Medical device company Zimmer Biomet (NYSE: ZBH) will be announcing earnings results tomorrow before market hours. Here’s what to expect.
Zimmer Biomet met analysts’ revenue expectations last quarter, reporting revenues of $2.02 billion, up 4.3% year on year. It was a slower quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates.
Is Zimmer Biomet a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Zimmer Biomet’s revenue to be flat year on year at $1.89 billion, slowing from the 3.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.77 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Zimmer Biomet has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Zimmer Biomet’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. CONMED delivered year-on-year revenue growth of 2.9%, beating analysts’ expectations by 2.6%, and BD reported revenues up 4.5%, falling short of estimates by 1.5%. CONMED traded up 16.9% following the results while BD was down 18.4%.
Read our full analysis of CONMED’s results here and BD’s results here.
There has been positive sentiment among investors in the healthcare equipment and supplies segment, with share prices up 4.9% on average over the last month. Zimmer Biomet is down 2.3% during the same time and is heading into earnings with an average analyst price target of $122.35 (compared to the current share price of $102.38).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
